Shilpa Medicare Ltd has reported a strong financial performance for the September quarter, clocking ₹3.7 billion in consolidated income from operations and ₹440.7 million in net profit. The results reflect operational resilience and strategic growth across its pharmaceutical segments, as per disclosures to NSE and BSE.
Shilpa Medicare Ltd (NSE: SHILPAMED) has released its consolidated financial results for the quarter ended September 2025, showcasing a solid uptick in operational and profitability metrics. The company continues to strengthen its foothold in the pharmaceutical sector, driven by strategic product expansion and cost optimization.
Key highlights:
- Total income from operations: ₹3.7 billion, indicating sustained revenue momentum across domestic and international markets
- Net profit after tax (PAT): ₹440.7 million, reflecting improved margins and efficient cost control
- Quarter-on-quarter (QoQ) trends:
- Revenue grew by 9.9% YoY, despite a slight QoQ dip of 2.82%
- Operating profit rose 3.16% QoQ to ₹251.6 million, though down 24.35% YoY
- Profit before tax surged 224.5% QoQ to ₹495.9 million, showcasing strong bottom-line recovery
- Strategic focus: Continued investment in oncology APIs, formulations, and global regulatory filings
These results underscore Shilpa Medicare’s strategic agility and operational discipline amid evolving market dynamics.
Sources: : Data compiled from Business Standard, NSE Circulars, and BSE Corporate Filings.